R&D News | pharmaphorum

News

AZ's Fasenra also works in rare organ damage diseases

AstraZeneca’s asthma drug Fasenra also works in a group of rare diseases that can lead to potentially fatal organ damage, a mid-stage trial has shown.

News

Merck's oral MS drug finally gets FDA okay

Merck KGaA has finally claimed an FDA approval for its oral multiple sclerosis therapy Mavenclad, eight years after being turned down by the US regulator.

News

Novartis buys NASH biotech IFM Tre in potential $1.575 bn de...

Novartis is to buy US biotech IFM Tre in a deal worth up to $1.575 billion, adding a potential drug for the fatty liver disease known as NASH to its pipeline.

News

Caucasian male with lack of sleep because he has flu stting in bed and ask for water or medicine. Concept ob being ill alone. Nobody can help him

'Man flu' is real, pharmaphorum research shows

‘Man flu’ is real, according to an exclusive trial carried out by pharmaphorum and based on a new methodology that could revolutionise research into some of the world’s most challenging dis

News

bluebird bio gets CHMP nod for gene therapy Zynteglo

A European Medicines Agency advisory panel has recommended a conditional approval for Zynteglo, bluebird bio’s lead gene therapy for thalassemia, a rare blood disorder.

News

Social psychology concept as a group of connected network of people icons with one individual brain illuminated as a symbol for sociology and group interaction.

Atai raises $43m to repurpose illicit drugs as medicines

Atai Life sciences has closed a $43 million second-round financing that will help it advance new medicines for mental illnesses derived from compounds in illicit drugs.

AZ's Fasenra also works in rare organ damage diseases

Merck's oral MS drug finally gets FDA okay

Novartis buys NASH biotech IFM Tre in potential $1.575 bn de...

'Man flu' is real, pharmaphorum research shows

bluebird bio gets CHMP nod for gene therapy Zynteglo

Atai raises $43m to repurpose illicit drugs as medicines

Bayer plans filings for cardiac amyloidosis imaging agent

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks